Clinical trials: Body Weight Control
Hypertension With Overweight or Obesity
Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity
The main objective of this study is to demonstrate the superior efficacy of HRS-7535 in controlling blood pressure compared to placebo in subjects with hypertension and overweight or obesity;
- Trial name
- NCT07528027
- Testing
- HRS-7535
- Where
- 2 sites in China
- Volunteers
- 648 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Overweight, Obesity
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background…
- Trial name
- ENLIGHTEN-6 (NCT07392190)
- Testing
- Eloralintide
- Where
- 185 sites in United States, Australia and 12 more
- Volunteers
- 900 people
- Sponsor
- Eli Lilly and Company
Obesity, Obstructive Sleep Apnea
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are receiving positive airway…
- Trial name
- MARITIME-OSA-1 (NCT07225686)
- Testing
- Maridebart cafraglutide
- Where
- 61 sites in United States, Australia and 9 more
- Volunteers
- 250 people
- Sponsor
- Amgen
Gut Health, Body Composition
A Clinical Trial to Evaluate the Effects of Cowboy Colostrum on Gut Health, Body Composition, Hair Growth, and Skin Appearance
This study evaluates the effects of Cowboy Colostrum bovine colostrum powder on gut health, body composition, hair growth, and skin appearance in generally healthy adults aged 21-47 with concerns in these areas.
- Conditions
- Gut Health, Body Composition, Hair Growth, Skin Appearance
- Trial name
- NCT07756866
- Testing
- Cowboy Colostrum
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Cowboy Colostrum
Obesity, Overweight
A Study to Evaluate the Drug Interactions of HRS-7535 With Acetaminophen, Digoxin, Rosuvastatin, and Omeprazole in Obese or Overweight Subjects
This study is an open-label, fixed-sequence, self-controlled Phase I clinical trial conducted among obese or overweight subjects, with a planned enrollment of 40 adult subjects.
- Trial name
- NCT07269756
- Testing
- HRS-7535 Tablets, Paracetamol Tablets, Digoxin Tablets
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial
The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity.
- Trial name
- NCT04847557
- Testing
- Tirzepatide
- Where
- 146 sites in United States, Argentina and 8 more
- Volunteers
- 731 people
- Sponsor
- Eli Lilly and Company
Overweight or Obesity, Healthy
A Study of LY4064912 in Healthy Participants and With Overweight or Obesity
The purpose of this study is to evaluate how well LY4064912 is tolerated and what side effects may occur in healthy participants and participants with overweight and obesity - global.
- Trial name
- YHAA (NCT07152002)
- Testing
- LY4064912
- Where
- 3 sites in United States, Singapore
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity
A Phase I Study of Single and Multiple Doses of HS-20136-2 Injection in Healthy or Obese Participants
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of HS-20136-2 injection in healthy/obese participants.
- Trial name
- NCT07716241
- Testing
- HS-20136-2
- Where
- China
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Obstructive Sleep Apnea (OSA)
Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) Therapy
This study is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase III clinical trial evaluating the efficacy and safety of GZR18 injection in obese subjects with moderate to severe obstructive sleep apnea…
- Trial name
- NCT07493057
- Testing
- GZR18 injection
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Cachexia, Cancer
Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Lung Cancer Patients
To test the compliance, tolerance, safety and to get preliminary insights into the efficacy of a new oral nutritional supplement (containing n-3 fatty acids, amino acids and antioxidants) designed to prevent or delay cachexia and…
- Trial name
- NCT00851448
- Testing
- oral nutritional supplement, food for special medical purposes
- Where
- 3 sites in Italy, Poland
- Volunteers
- 17 people
- Sponsor
- Fresenius Kabi
Overweight or Obesity
A Study of ZT002 Injection in Participants With Overweight or Obesity
This study will comprise a randomized, double-blind, placebo-controlled, multiple-ascending-dose, safety, tolerability, and pharmacokinetics study of ZT002 in participants with Overweight or Obesity.
- Trial name
- NCT06371326
- Testing
- ZT002 Injection
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Obesity, Overweight
A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants with obesity or who are…
- Trial name
- NCT06525935
- Testing
- Enicepatide
- Where
- 34 sites in United States
- Volunteers
- 469 people
- Sponsor
- Carmot Therapeutics, Inc.
Obesity, Overweight
A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)
The study compares the effectiveness of treatment options for weight management after discontinuing semaglutide and tirzepatide. The primary outcome is absolute and percentage weight change at 12-weeks.
- Trial name
- NCT06605703
- Testing
- WW Clinic, Bupropion-Naltrexone, Bupropion-Naltrexone-Metformin
- Where
- United States
- Volunteers
- 226 people
- Sponsor
- WW International Inc
Type 2 Diabetes Mellitus
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide.
- Trial name
- REIMAGINE 2 (NCT06065540)
- Testing
- Cagrilintide, Semaglutide
- Where
- 405 sites in United States, Argentina and 30 more
- Volunteers
- 2,734 people
- Sponsor
- Novo Nordisk A/S
Overweight and Obesity
Efficacy and Safety of Glucosanol™ in Body Weight Reduction
It was proven in a previous clinical study that Glucosanol™ is effective and safe in reducing weight in the overweight and obese.
- Trial name
- NCT02930668
- Testing
- Glucosanol 350mg, Glucosanol 500mg
- Where
- Germany
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Overweight, Obesity
Weight and Metabolic Management Study
The goal of this clinical trial is to learn whether elénzia CONTROL®, a nutritional supplement, can support weight management in adults who have either never used GLP-1 weight-loss medications or have recently stopped using them.
- Conditions
- Overweight, Obesity, Weight Maintenance
- Trial name
- WMMS (NCT07789223)
- Testing
- elénzia CONTROL®
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Elenzia
Overweight, Obesity
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
This study will look at how much cagrilintide helps people with overweight or obesity and type 2 diabetes lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide.
- Conditions
- Overweight, Obesity, Type 2 Diabetes
- Trial name
- RENEW 2 (NCT07220759)
- Testing
- Cagrilintide
- Where
- 67 sites in United States, Argentina and 9 more
- Volunteers
- 330 people
- Sponsor
- Novo Nordisk A/S
Obese, Overweight
A Study of SA030 Injection in Overweight or Obese Participants
This study is the first time SA030 is being given to people. The goal is to understand how safe it is, how well it is tolerated, and how the body processes and responds to a single dose of SA030 in individuals who are overweight…
- Trial name
- NCT07479862
- Testing
- SA030 Injection
- Where
- 2 sites in Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Suzhou Siran Biotechnology Co.,Ltd.
Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
- Trial name
- MARITIME-HF (NCT07037459)
- Testing
- Maridebart cafraglutide
- Where
- 686 sites in United States, Argentina and 33 more
- Volunteers
- 5,056 people
- Sponsor
- Amgen
Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)
A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants who are overweight or obese…
- Trial name
- NCT06628362
- Testing
- Enicepatide
- Where
- 70 sites in United States, Argentina and 4 more
- Volunteers
- 447 people
- Sponsor
- Carmot Therapeutics, Inc.